The aim of this secondary analysis of a randomized controlled trial was to test whether the I148M variant of Patatin-like phospholipase domain-containing protein-3 (PNPLA3) is associated with the response to docosahexaenoic acid (DHA) in children with non-Alcoholic fatty liver disease (NAFLD). Sixty children with NAFLD were randomized in equal numbers to DHA 250 mg/day, DHA 500 mg/day or placebo. Coherently with the primary analysis, the probability of more severe steatosis after 24 months of DHA supplementation was 50% lower [95% confidence interval (CI) -59% to -42%)] in the combined DHA 250 and 500 mg/day groups versus placebo. The present secondary analysis revealed an independent effect of PNPLA3 status on the response to DHA. In fact, the probability of more severe steatosis was higher (37%, 95% CI 26-48%) for the PNPLA3 M/M versus I/M genotype and lower (-12%, 95% CI -21% to -3%) for the I/I versus I/M genotype (Somers' D for repeated measures). We conclude that the 148M allele of PNPLA3 is associated with lower response, and the 148I allele with greater response, to DHA supplementation in children with NAFLD. © Copyright 2013, Mary Ann Liebert, Inc. and Korean Society of Food Science and Nutrition 2013.

The I148M variant of PNPLA3 reduces the response to docosahexaenoic acid in children with non-Alcoholic fatty liver disease / V. Nobili, G. Bedogni, B. Donati, A. Alisi, L. Valenti. - In: JOURNAL OF MEDICINAL FOOD. - ISSN 1096-620X. - 16:10(2013 Sep 28), pp. 957-960.

The I148M variant of PNPLA3 reduces the response to docosahexaenoic acid in children with non-Alcoholic fatty liver disease

G. Bedogni;B. Donati;L. Valenti
2013

Abstract

The aim of this secondary analysis of a randomized controlled trial was to test whether the I148M variant of Patatin-like phospholipase domain-containing protein-3 (PNPLA3) is associated with the response to docosahexaenoic acid (DHA) in children with non-Alcoholic fatty liver disease (NAFLD). Sixty children with NAFLD were randomized in equal numbers to DHA 250 mg/day, DHA 500 mg/day or placebo. Coherently with the primary analysis, the probability of more severe steatosis after 24 months of DHA supplementation was 50% lower [95% confidence interval (CI) -59% to -42%)] in the combined DHA 250 and 500 mg/day groups versus placebo. The present secondary analysis revealed an independent effect of PNPLA3 status on the response to DHA. In fact, the probability of more severe steatosis was higher (37%, 95% CI 26-48%) for the PNPLA3 M/M versus I/M genotype and lower (-12%, 95% CI -21% to -3%) for the I/I versus I/M genotype (Somers' D for repeated measures). We conclude that the 148M allele of PNPLA3 is associated with lower response, and the 148I allele with greater response, to DHA supplementation in children with NAFLD. © Copyright 2013, Mary Ann Liebert, Inc. and Korean Society of Food Science and Nutrition 2013.
children; docosahexaenoic acid; non-Alcoholic fatty liver disease; randomized controlled trial; Child; Child, Preschool; Docosahexaenoic Acids; Fatty Liver; Female; Humans; Lipase; Male; Membrane Proteins; Treatment Outcome; Mutation, Missense; Medicine (miscellaneous); Nutrition and Dietetics
Settore MED/09 - Medicina Interna
Centro per lo studio e la cura delle malattie metaboliche del fegato
Article (author)
File in questo prodotto:
File Dimensione Formato  
food.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 92.33 kB
Formato Adobe PDF
92.33 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/249529
Citazioni
  • ???jsp.display-item.citation.pmc??? 21
  • Scopus 55
  • ???jsp.display-item.citation.isi??? 51
social impact